Background
High altitude is a challenging condition caused by insufficient oxygen (O2) supply. Inability to adjust to hypoxia may lead to pulmonary edema, stroke, cardiovascular dysfunction and even death. Thus, understanding the molecular basis of adaptation to high altitude may reveal novel therapeutics to counteract the detrimental consequences of hypoxia.
Methods
Using high throughput unbiased metabolomic profiling, we report that the metabolic pathway responsible for production of erythrocyte 2,3-bisphosphoglycerate (2,3-BPG), a negative allosteric regulator of hemoglobin-O2 binding affinity, was significantly induced in 21 healthy humans within two hours of arrival at 5260m, and further increased following 16 days at 5260m.
Results
This finding led us to uncover discover that plasma adenosine concentrations and soluble CD73 (sCD73) activity rapidly increased at high altitude and were associated with elevated erythrocyte 2,3-BPG levels and O2 releasing capacity. Mouse genetic studies demonstrated that elevated CD73 contributed to hypoxia-induced adenosine accumulation and that elevated adenosine-mediated erythrocyte A2B adenosine receptor (ADORA2B) activation was beneficial by inducing 2,3-BPG production, triggering O2 release to prevent multiple tissue hypoxia, inflammation and pulmonary vascular leakage. Mechanistically, we demonstrated that erythrocyte AMP-activated protein kinase (AMPK) was activated in humans at high altitude and that AMPK is a key protein functioning downstream of ADORA2B, phosphorylating and activating BPG mutase and in this way inducing 2,3-BPG production and O2 release from erythrocytes. Significantly, preclinical studies demonstrated that activation of AMPK enhanced BPG mutase activation, 2,3-BPG production and O2 release capacity in CD73-deficient mice, in erythrocyte specific ADORA2B knockouts, and in wild type mice and in turn reduced tissue hypoxia, and inflammation.
Conclusions
Altogether, both human and mouse studies reveal novel mechanisms of hypoxia adaptation and potential therapeutic approaches for counteracting hypoxia-induced tissue damage.